Oncternal Therapeutics (NASDAQ:ONCT) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a research report report published on Tuesday morning. The brokerage issued a hold rating on the stock.

Several other brokerages also recently commented on ONCT. HC Wainwright dropped their target price on shares of Oncternal Therapeutics from $19.00 to $18.00 and set a buy rating on the stock in a report on Monday, August 12th. Northland Capmk downgraded shares of Oncternal Therapeutics from a strong-buy rating to a hold rating in a research report on Thursday, September 12th. Brookline Capital Management reaffirmed a hold rating on shares of Oncternal Therapeutics in a research report on Thursday, September 12th. Finally, Northland Securities reiterated a market perform rating and set a $2.00 target price on shares of Oncternal Therapeutics in a report on Thursday, September 12th. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of Hold and a consensus target price of $20.00.

Oncternal Therapeutics Stock Up 2.1 %

Shares of ONCT stock opened at $1.45 on Tuesday. Oncternal Therapeutics has a 12-month low of $1.32 and a 12-month high of $13.14. The firm has a fifty day moving average of $4.43 and a 200-day moving average of $7.01. The firm has a market capitalization of $4.29 million, a price-to-earnings ratio of -0.12 and a beta of 1.39.

Oncternal Therapeutics (NASDAQ:ONCT) last posted its earnings results on Thursday, August 8th. The company reported ($2.89) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.03) by $0.14. The firm had revenue of $0.80 million during the quarter, compared to analysts’ expectations of $0.24 million. Oncternal Therapeutics had a negative return on equity of 136.10% and a negative net margin of 1,948.70%. During the same period in the previous year, the firm earned ($3.00) earnings per share. Research analysts expect that Oncternal Therapeutics will post -11.43 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Oncternal Therapeutics stock. Pasadena Private Wealth LLC acquired a new position in shares of Oncternal Therapeutics, Inc. (NASDAQ:ONCT) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 25,000 shares of the company’s stock, valued at approximately $190,000. Pasadena Private Wealth LLC owned about 0.84% of Oncternal Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 16.05% of the company’s stock.

About Oncternal Therapeutics

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.